New longer-term results show a survival benefit from adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to first-line chemotherapy for women with metastatic triple-negative breast cancer ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results